SM
Stergios J. Moschos
Highly rated in
5
conditions
Highly rated in
5
conditions
Areas of Expertise
Check Dr. Stergios J. Moschos' experience treating your condition:
About Dr. Stergios J. Moschos

Stergios Moschos is a Hematologist and a Hematologist Oncology expert in Chapel Hill, North Carolina. Moschos has been practicing medicine for over 26 years and is highly rated in 5 conditions, according to our data. His top areas of expertise are Melanoma, Melanoma of the Eye, Metastatic Brain Tumor, and Brain Tumor. He is licensed to treat patients in North Carolina. Moschos is currently accepting new patients.

His clinical research consists of co-authoring 65 peer reviewed articles and participating in 10 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Stergios J. Moschos it is best to call his office and ask if your insurance is accepted.

Accepts Medicare

Dr. Stergios J. Moschos accepts the following insurance:

  •  Blue Cross Blue Shield
  •  Ambetter
  •  UnitedHealthcare

Call to see if your plan is accepted.
Locations
101 Manning Dr, 2nd Floor, Chapel Hill, NC 27514
Background & Education
Graduate Institution
Other, 1997
Specialties
Hematology
Hematology Oncology
Licenses
Internal Medicine in NC
Hospital Affiliations
UNC Medical Center
UNC Rockingham Health Care
Chatham Hospital
UNC Lenoir Health Care
Caldwell UNC Health Care
Languages Spoken
English
Greek
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


8 Clinical Trials

Breaking Innate PD-1 Inhibitor (PD1i) Resistance Using Epigenetic Modifiers; Antitumor Efficacy and Correlative Analyses of Entinostat Plus Pembrolizumab in Non-Inflamed Metastatic Melanoma (MM)
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 3 Trial of Adjuvant Avelumab (Anti-PDL-1 Antibody) in Merkel Cell Carcinoma Patients With Lymph Node Metastases
Pembrolizumab in Systemic Treatment-Naïve Distant Metastatic Melanoma and Exploration of Use of Baseline 11C-methyl-L-tryptophan (C11-AMT) PET Imaging as a Predictive Imaging Biomarker of Antitumor Response
Phase 2 Study of Denosumab in Combination With a PD-1 Inhibitor in Subjects With Stage III/IV Melanoma
Phase I/II Study of Dabrafenib, Trametinib, and Navitoclax in BRAF Mutant Melanoma (Phase I and II) and Other Solid Tumors (Phase I Only)
A Phase 2 Study of Ibrutinib (PCI-32765) in Refractory Distant Metastatic Cutaneous Melanoma: Correlation of Biomarkers With Response and Resistance
View 6 Less Clinical Trials -

65 Total Publications

War against NRAS-Mutant Melanoma Using Targeted Therapies Remains Challenging.


Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors